virus
The Italian agency ANSA reported that the first drug that attacks the Corona virus has been developed, based on a monoclonal antibody, and it is useful to identify the protein that the virus uses to attack the cells of the respiratory system.
The Italian agency said today, Saturday, that the research was published on the "BioRxiv" website by a team at the Dutch University of Utrecht headed by researcher Shonian Wang.
It will take months before the medicine becomes available because it will have to be tested for answers to its safety and efficacy, the researchers told the BBC.
The research indicated that by binding to the Spike protein found on the surface of the Corona virus, the monoclonal antibody is prevented from binding to cells, and in this way it becomes impossible to penetrate the virus into it to reproduce.
For this reason, he added, researchers are convinced that antibodies have important potential "for the treatment and prevention of Covid-19".
The Italian agency explained that the researchers were already working on an antibody to "Sars" when the "Covid-19" or "Sars2" epidemic exploded, and they realized that effective antibodies against the first disease could prevent the second as well.
The researchers confirmed that studies are still underway, and that the antibody must undergo very strict tests.
The researchers hope to persuade pharmaceutical companies to manufacture the new drug, stressing that this will allow the development of a vaccine against the emerging virus.
Source: Italian "Ansa" agency
The Italian agency ANSA reported that the first drug that attacks the Corona virus has been developed, based on a monoclonal antibody, and it is useful to identify the protein that the virus uses to attack the cells of the respiratory system.
The Italian agency said today, Saturday, that the research was published on the "BioRxiv" website by a team at the Dutch University of Utrecht headed by researcher Shonian Wang.
It will take months before the medicine becomes available because it will have to be tested for answers to its safety and efficacy, the researchers told the BBC.
The research indicated that by binding to the Spike protein found on the surface of the Corona virus, the monoclonal antibody is prevented from binding to cells, and in this way it becomes impossible to penetrate the virus into it to reproduce.
For this reason, he added, researchers are convinced that antibodies have important potential "for the treatment and prevention of Covid-19".
The Italian agency explained that the researchers were already working on an antibody to "Sars" when the "Covid-19" or "Sars2" epidemic exploded, and they realized that effective antibodies against the first disease could prevent the second as well.
The researchers confirmed that studies are still underway, and that the antibody must undergo very strict tests.
The researchers hope to persuade pharmaceutical companies to manufacture the new drug, stressing that this will allow the development of a vaccine against the emerging virus.
Source: Italian "Ansa" agency
ليست هناك تعليقات:
إرسال تعليق